keyword
MENU ▼
Read by QxMD icon Read
search

mRcc

keyword
https://www.readbyqxmd.com/read/29045250/clinical-decision-making-for-immunotherapy-in-metastatic-renal-cell-carcinoma
#1
Manuela Schmidinger
PURPOSE OF REVIEW: To review the treatment options in metastatic renal cell carcinoma (mRCC) in the light of new immunotherapy results. RECENT FINDINGS: Second-line treatment strategies for treatment of mRCC after progression on first-line VEGF-targeted therapy have recently undergone a major change. Treatment guidelines currently recommend the use of either nivolumab, a programmed cell death 1 (PD-1) inhibitor, or cabozantinib, an inhibitor of multiple receptor tyrosine kinases, as preferred choices...
October 17, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29041991/neutrophil-lymphocyte-ratio-and-duration-of-prior-anti-angiogenic-therapy-as-biomarkers-in-metastatic-rcc-receiving-immune-checkpoint-inhibitor-therapy
#2
Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana, Ulka Vaishampayan
BACKGROUND: There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocyte ratio (NLR) and duration of prior anti-vascular endothelial growth factor (VEGF) inhibitors, as predictors of response rate, progression free survival (PFS) and overall survival (OS) in mRCC patients treated with immune checkpoint inhibitor (ICI). METHODS: Regulatory approval was obtained...
October 17, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29030073/comparative-analysis-of-surgery-thermal-ablation-and-active-surveillance-for-renal-oncocytic-neoplasms
#3
Brady L Miller, Lori Mankowski Gettle, Jason R Van Roo, Timothy J Ziemlewicz, Sara L Best, Shane A Wells, Meghan G Lubner, J Louis Hinshaw, Fred T Lee, Stephen Y Nakada, Wei Huang, E Jason Abel
OBJECTIVE: To compare oncologic and procedural outcomes for renal oncocytic tumors treated with surgery, thermal ablation or active surveillance. METHODS AND MATERIALS: Clinical and pathologic data were collected for consecutive patients with a histological diagnosis of oncocytoma, oncocytic neoplasm or chromophobe renal cell cancers (chRCC) from 2003-2016. Independent pathology and radiology review was performed for this study. RESULTS: Of 171 patients, tumor histology included oncocytoma (n=122), chRCC (n=47) and oncocytic neoplasm not otherwise specified (n=2)...
October 10, 2017: Urology
https://www.readbyqxmd.com/read/29027615/assessment-of-the-role-of-everolimus-therapy-in-patients-with-renal-cell-carcinoma-based-on-daily-routine-and-recent-research-results
#4
Anikó Maráz, András Csejtei, Judit Kocsis, Miklós Szűcs, Zsuzsanna Kahán, György Bodoky, Magdolna Dank, László Mangel, János Révész, Zoltán Varga, Lajos Géczi
Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome. Data of 165 patients from 9 oncology institutes in Hungary were analyzed retrospectively. Everolimus therapy was used after one TKI in 10 mg starting dose...
October 13, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28992528/adjuvant-therapy-in-renal-cell-carcinoma
#5
REVIEW
Francesco Massari, Vincenzo Di Nunno, Chiara Ciccarese, Jeffrey Graham, Camillo Porta, Francesca Comito, Marta Cubelli, Roberto Iacovelli, Daniel Y C Heng
Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored...
September 23, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28986088/expression-of-tyrosine-kinase-receptor-axl-is-associated-with-worse-outcome-of-metastatic-renal-cell-carcinomas-treated-with-sunitinib
#6
Luís Eduardo Zucca, Mariana Andozia Morini Matushita, Renato José da Silva Oliveira, Cristovam Scapulatempo-Neto, Marcos Alves de Lima, Guilherme Gomes Ribeiro, Cristiano Ribeiro Viana, Flavio Mavignier Cárcano, Rui Manuel Reis
BACKGROUND: Renal cell carcinoma (RCC) represents 2%-3% of all cancers of the Western countries. Currently, sunitinib, a receptor tyrosine kinase inhibitor, particularly of PDGF and VEGF receptors, is the first-line therapy for metastatic RCC (mRCC), with significant improvement in clinical outcome. However, there is a lack of predictive biomarkers of sunitinib response. Recently, others and our group suggested that the receptor tyrosine kinase AXL may modify the response to sunitinib...
October 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28978162/effects-of-vegf-and-vegfr-polymorphisms-on-the-outcome-of-patients-with-metastatic-renal-cell-carcinoma-treated-with-sunitinib-a-systematic-review-and-meta-analysis
#7
Chenkui Miao, Jingyi Cao, Yuhao Wang, Bianjiang Liu, Zengjun Wang
To summarize and clarify the association between vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms and the outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. A total of 8 studies including 900 patients were analyzed in this systematic review after screening the database of PubMed, EMBASE and Web of Science. Hazard ratios (HRs) with 95% confidence interval (CI) were used to evaluate the strength of the association...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28977627/baseline-risk-stratification-or-duration-of-prior-therapy-predicts-prognosis-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-axitinib
#8
Ryuichi Mizuno, Shuji Mikami, Kimiharu Takamatsu, Toshiaki Shinojima, Eiji Kikuchi, Mototsugu Oya
Background: To elucidate the clinical prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with axitinib. Methods: A total of 58 patients were retrospectively analyzed. All patients received axitinib treatment for mRCC at Keio University hospital in Japan. Baseline clinical factors and on treatment adverse events were assessed to predict survival. Results: The median progression free survival (PFS) for axitinib treatment was 10...
September 18, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28974985/cabozantinib-in-metastatic-renal-cell-carcinoma-latest-findings-and-clinical-potential
#9
REVIEW
Melissa Bersanelli, Sebastiano Buti
Since the advent of immunotherapy revolutionized the treatment of metastatic renal cell carcinoma (mRCC), the attention of oncologists has been unavoidably shifted from tyrosine kinase inhibitors (TKIs) to immune checkpoint blockade, with the associated risk of listing cabozantinib as just one of many available TKIs. On the contrary, we think that cabozantinib represents a very good option for mRCC treatment, with outstanding outcomes in terms of response rate, progression-free survival, overall survival and quick time to treatment response...
October 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28969022/plasma-exosomal-mirnas-based-prognosis-in-metastatic-kidney-cancer
#10
Meijun Du, Karthik V Giridhar, Yijun Tian, Michael R Tschannen, Jing Zhu, Chiang-Ching Huang, Deepak Kilari, Manish Kohli, Liang Wang
Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ∼3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysis. Cox regression analysis identified association of 6 miRNAs with overall survival (OS) (P<0.01, False discovery rate (FDR) < 0.3). Five of the associated miRNAs were quantified in an independent follow-up cohort of 65 mRCC patients by TaqMan-based miRNA assays...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28966072/sunitinib-dose-escalation-after-disease-progression-in-metastatic-renal-cell-carcinoma
#11
Jacques Raphael, Alia Thawer, Georg A Bjarnason
PURPOSE: Previous pharmacologic studies demonstrated that higher sunitinib exposure is associated with improved clinical outcomes in patients with metastatic renal cell carcinoma (mRCC). We aimed to assess the efficacy and toxicity of sunitinib dose-escalation in mRCC patients progressing on the standard 50mg dose. METHODS: A single-institution retrospective review was conducted on mRCC patients, treated outside trials with a 50mg sunitinib dose given on an individualized schedule between October 2009 and January 2016, who subsequently progressed on imaging...
September 28, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28963640/development-of-response-classifier-for-vascular-endothelial-growth-factor-receptor-vegfr-tyrosine-kinase-inhibitor-tki-in-metastatic-renal-cell-carcinoma
#12
Heounjeong Go, Mun Jung Kang, Pil-Jong Kim, Jae-Lyun Lee, Ji Y Park, Ja-Min Park, Jae Y Ro, Yong Mee Cho
Vascular endothelial growth factor receptor (VEGFR)-targeted therapy improved the outcome of metastatic renal cell carcinoma (mRCC) patients. However, a prediction of the response to VEGFR-tyrosine kinase inhibitor (TKI) remains to be elucidated. We aimed to develop a classifier for VEGFR-TKI responsiveness in mRCC patients. Among 101 mRCC patients, ones with complete response, partial response, or ≥24 weeks stable disease in response to VEGFR-TKI treatment were defined as clinical benefit group, whereas patients with <24 weeks stable disease or progressive disease were classified as clinical non-benefit group...
September 29, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28950297/a-randomized-phase-2-trial-of-crlx101-in-combination-with-bevacizumab-versus-standard-of-care-in-patients-with-advanced-renal-cell-carcinoma
#13
M H Voss, A Hussain, N Vogelzang, J L Lee, B Keam, S Y Rha, U Vaishampayan, W B Harris, S Richey, J M Randall, D Shaffer, A Cohn, T Crowell, J Li, A Senderowicz, E Stone, R Figlin, R J Motzer, N B Haas, T Hutson
Background: Nanoparticle-drug conjugates (NDC) enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel NDC containing camptothecin a potent inhibitor of topoisomerase I and the hypoxia-inducible factors (HIF) 1α and 2α. In a phase 1b/2 trial, CRLX101+bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase 2 trial comparing CRLX101+bevacizumab versus standard of care (SOC) in refractory mRCC...
September 11, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28932952/survival-of-metastatic-renal-cell-carcinoma-patients-continues-to-improve-over-time-even-in-targeted-therapy-era
#14
Michele Marchioni, Marco Bandini, Raisa S Pompe, Zhe Tian, Tristan Martel, Anil Kapoor, Luca Cindolo, Francesco Berardinelli, Alberto Briganti, Shahrokh F Shariat, Luigi Schips, Pierre I Karakiewicz
OBJECTIVE: To examine the effect of diagnosis year, defined as contemporary (2010-2014), intermediate (2006-2009) and historical (2001-2005) on cancer-specific mortality (CSM) in patients with metastatic renal cell carcinoma (mRCC). METHODS: Within Surveillance, Epidemiology, and End Results registry (2001-2014), we identified patients with mRCC. Cumulative incidence and competing risks regression (CRR) models examined CSM, after accounting for other-cause mortality...
September 20, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28919536/neuroprotective-effect-of-5%C3%A9-androst-3%C3%AE-5-6%C3%AE-triol-on-retinal-ganglion-cells-in-a-rat-chronic-ocular-hypertension-model
#15
Yan-Qiu Chen, Shu-Min Zhong, Shu-Ting Liu, Feng Gao, Fang Li, Yuan Zhao, Xing-Huai Sun, Yanying Miao, Zhongfeng Wang
Previous studies have demonstrated that 5ɑ-androst-3β,5,6β-triol (Triol), a synthesized steroid compound, showed notable neuroprotective effect in cultured cortical neurons. In the present study, we explored whether and how Triol have neuroprotective effect on retinal ganglion cells (RGCs) in a chronic ocular hypertension (COH) rat model. COH model was produced by injecting superparamagnetic iron oxide micro-beads into the anterior chamber, and Triol was administrated (4.8μg/100g, i.p., once daily for 4 weeks)...
September 15, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28918459/hla-class-i-expression-predicts-prognosis-and-therapeutic-benefits-from-tyrosine-kinase-inhibitors-in-metastatic-renal-cell-carcinoma-patients
#16
Jiajun Wang, Li Liu, Yang Qu, Wei Xi, Yu Xia, Qi Bai, Ying Xiong, Qilai Long, Jiejie Xu, Jianming Guo
PURPOSE: Classical HLA class I antigen is highly involved in antigen presentation and adaptive immune response against tumor. In this study, we explored its predictive value for treatment response and survival in metastatic renal-cell carcinoma (mRCC) patients. EXPERIMENTAL DESIGN: A TKI cohort of 111 mRCC patients treated with sunitinib or sorafenib and a non-TKI cohort of 160 mRCC patients treated with interleukin-2 or interferon-α-based immunotherapy at a single institution were retrospectively enrolled...
September 16, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28917029/health-related-quality-of-life-and-its-determinants-in-patients-with-metastatic-renal-cell-carcinoma
#17
S de Groot, W K Redekop, M M Versteegh, S Sleijfer, E Oosterwijk, L A L M Kiemeney, C A Uyl-de Groot
PURPOSE: Based on improvements of progression-free survival (PFS), new agents for metastatic renal cell carcinoma (mRCC) have been approved. It is assumed that one of the benefits is a delay in health-related quality of life (HRQoL) deterioration as a result of a delay in progression of disease. However, little data are available supporting this relationship. This study aims to provide insight into the most important determinants of HRQoL (including progression of disease) of patients with mRCC...
September 15, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28889323/significance-of-preoperative-prognostic-nutrition-index-as-prognostic-predictors-in-patients-with-metastatic-renal-cell-carcinoma-with-tyrosine-kinase-inhibitors-as-first-line-target-therapy
#18
Wen Cai, Hai Zhong, Wen Kong, Baijun Dong, Yonghui Chen, Lixin Zhou, Wei Xue, Yiran Huang, Jin Zhang, Jiwei Huang
OBJECTIVE: Prognostic nutritional index (PNI) is a recognized indicator of both immune and nutritional status. It was firstly used as a preoperative prognostic indicator, and its role in the prognosis of patients with metastatic renal cell carcinoma (mRCC) has not yet been investigated in large-scale study. The purpose of this work was to investigate the prognostic role of pretreatment PNI in patients with mRCC with sorafenib or sunitinib as first-line targeted therapy. METHOD: In this retrospective single-center research, the Kaplan-Meier method was used to estimate the progression-free survival (PFS) and overall survival (OS) of 178 mRCC patients who received first-line therapy of sorafenib or sunitinib...
November 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28887097/second-line-systemic-therapy-in-metastatic-renal-cell-carcinoma-a-review
#19
REVIEW
Rohit K Jain, Shipra Gandhi, Saby George
Treatment in metastatic renal-cell carcinoma (mRCC) has evolved tremendously in the last decade. The development of newer targeted agents, like vascular endothelial growth factor inhibitors and immunotherapy have changed the treatment paradigm in mRCC patients. Axitinib and everolimus have been used extensively in patients who progressed on prior antiangiogenic therapy. The newer agents including nivolumab, cabozantinib, and lenvatinib in combination with everolimus have all demonstrated overall survival benefit over everolimus...
September 5, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28886476/phase-i-study-of-axitinib-and-everolimus-in-metastatic-solid-tumours-and-extension-to-metastatic-renal-cell-carcinoma-results-of-evax-study
#20
Alain Ravaud, Carlos Gomez-Roca, Marie-Quitterie Picat, Laurence Digue, Christine Chevreau, Anne Gimbert, Emmanuelle Chauzit, Rémi Sitta, François Cornelis, Julien Asselineau, Richard Aziza, Amaury Daste, Cathy Quemener, Jessica Baud, Andréas Bikfalvi, Delphine Pedenon-Périchout, Adelaïde Doussau, Mathieu Molimard, Jean-Pierre Delord
PURPOSE: Anti-angiogenic and mammalian target of rapamycin inhibitors have shown efficacy in solid tumours. Reported combination of both drugs was deemed to be too toxic. Due to a potential favourable safety profile of axitinib (AX), a phase I study combining everolimus (EV) and AX for solid tumours was explored. EXPERIMENTAL DESIGN: Patients (pts) with advanced cancers were enrolled in an escalation phase I study to investigate the safety of the combination. Pharmacokinetic profile and functional vascular imaging were performed...
November 2017: European Journal of Cancer
keyword
keyword
77808
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"